Bristol Myers Squibb Builds Largest NVIDIA Life-Sciences AI Supercomputer After 3-Year Partnership
Updated
Updated · STAT · Jul 20
Bristol Myers Squibb Builds Largest NVIDIA Life-Sciences AI Supercomputer After 3-Year Partnership
3 articles · Updated · STAT · Jul 20
Summary
Bristol Myers Squibb said it is assembling what it calls the largest NVIDIA AI supercomputer in life sciences, the third such claim by a pharma company in nine months.
3 years into its NVIDIA partnership, BMS said its earlier computing cluster was fully used as its AI work expanded beyond tools like protein structure prediction.
Foundation models are driving the buildout because they require far more computing power to analyze how drug candidates interact with the body and disease, according to Chief Digital and Technology Officer Greg Meyers.
BMS said it has already developed such models in oncology and neurodegeneration, underscoring how large-scale AI infrastructure is becoming central to drug discovery.
In the pharma AI arms race, is the biggest supercomputer the key or is proprietary biological data the real kingmaker?
Pharma is betting billions on AI, but can supercomputers solve the human biology puzzle that still stumps scientists?
BMS and NVIDIA Deploy Record-Breaking AI Supercomputer, Ushering in a New Era of Drug Development
Overview
Bristol Myers Squibb (BMS) has launched the life sciences sector’s most powerful and energy-efficient AI supercomputer, the NVIDIA DGX SuperPOD, to accelerate drug discovery and development. This new system is not just about having the largest compute power; it is carefully integrated across every stage of BMS’s research and development pipeline. With a strategic allocation plan, the 'SuperDuperPOD' supports various scientific approaches and is present at every step, reflecting BMS’s commitment to using AI for transformative impact. This builds on a strong, ongoing collaboration between BMS and NVIDIA, aiming to revolutionize how medicines are discovered.